{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"MTD will be defined as the dose level at which fewer than one-third of participants experience a dose-limiting toxicity attributable to pembrolizumab and trebananib, as determined using a standard 3+3 dose-escalation design.","groups":[{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 15 mg/kg or 30mg/kg weekly.","id":"OG000","title":"[Dose Escalation Dose Level I and Dose Level II] Pembrolizumab + Trebananib"}],"paramType":"NUMBER","populationDescription":"This analysis applies only to patients who were enrolled and treated during the dose-escalation period.","reportingStatus":"POSTED","timeFrame":"3 weeks","title":"Maximum Tolerated Dose (MTD) of Trebananib","type":"PRIMARY","unitOfMeasure":"mg/kg"}